Tadeusz Wesołowski, PhD, who is an investor engaging in listed companies from the medical and biotechnology sector, as well as his controlled entity, have increased their stake in BRASTER S.A. Currently, they hold 10.6% of stake in capital and votes at the General Shareholders’ Meeting (GSM) of the Company.
On Friday, April 10, the Company was notified that Tadeusz Wesołowski (along with his controlled entity) had exceeded the 10% threshold in votes at the GSM of BRASTER S.A. The last transactions at the stock-exchange session before exceeding the threshold were made at an average price of PLN 19.94. Currently, Tadeusz Wesołowski holds 303,300 shares in the Company (directly and through his controlled entity), accounting for 10.06% of the share capital and entitling to 10.06% of votes at the GSM.
“I am very happy that Tadeusz Wesołowski has increased his stake in Braster’s shares. It proves that he is convinced of the Company’s potential and the technology it develops,” says President of the Management Board of BRASTER S.A Marcin Halicki.
On February 16, 2015, Tadeusz Wesołowski informed that he had exceeded 5% in the Company’s capital, which means that he has bought 117,779 shares since then.
According to publicly available data, other shareholders with over 5% stake in Braster include Towarzystwo Funduszy Inwestycyjnych S.A., which are funds controlled by Ipopema (Ipopema TFI), Dom Maklerski Banku Ochrony Środowiska S.A. (DM BOŚ) and representatives of the Company’s management: Member of the Supervisory Board Grzegorz Pielak and Vice-President of the Management Board Henryk Jaremek, PhD, Eng. Another shareholder of Braster is President of the Board Marcin Halicki, who, shortly after taking up his position in October last year, bought a total of 58,072 Company’s shares for PLN 420,000, thereby acquiring 1.93% of the BRASTER S.A share capital and votes at the General Meeting.
On April 8, the Company informed that its main shareholders and representatives of the Company’s management had concluded lock-up agreements, which would be in force as from the moment of setting the final price in the new offer. Two largest institutional investors, DM BOŚ and Ipopema TFI, which hold 10.85% and 10.63%, respectively, of shares in the Company’s share capital and the same share in votes at the General Shareholders’ Meeting, committed not to sell their shares. The agreement was also signed by representatives of the Management Board: Marcin Halicki, Henryk Jaremek and Konrad Kowalczuk, as well as Members of the Supervisory Board Grzegorz Pielak and Tomasz Binkiewicz.
At the end of January, the Company filed a request to the Polish Financial Supervision Authority for renewal of proceedings on approval of the Issuing Prospectus. The approval of the prospectus will allow the Company to move its quotations to the main market of the Warsaw Stock Exchange (WSE).